Jaguar Health

209 articles about Jaguar Health

• Jaguar Health to Present at Lytham Partners Spring 2023 Investor Conference & Participate in Animal Health Panel

  5/16/2023

  Jaguar Health, Inc today announced that on Thursday, May 18, 2023 Lisa Conte, Jaguar's president, founder, and CEO, will present at the virtual Lytham Partners Spring 2023 Investor Conference and take part in an Animal Health Panel Discussion during the event.

• Jaguar Health Reports First Quarter 2023 Financial Results

  5/15/2023

  Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated first-quarter 2023 financial results and provided Company updates.

• Canalevia-CA1, Jaguar Animal Health’s FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs, Now Available from Chewy

  5/11/2023

  Jaguar Health, Inc. under its Jaguar Animal Health tradename for the veterinary market, announced that Canalevia-CA1, the company's U.S. Food and Drug Administration conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs, is now available on Chewy, a trusted destination for pet parents and partners everywhere.

• Jaguar Health Launches AI-powered Web Portal to Support Patient Access to Mytesi, the Company's FDA-approved Prescription Drug

  5/10/2023

  Jaguar Health, Inc. today announced that the Company has launched an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi (crofelemer).

• Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea

  5/9/2023

  Jaguar Health, Inc. today announced that it has completed enrolling the target number of 256 patients in the Company's global, pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy.

• Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates

  5/8/2023

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, May 15, 2023 at 8:30 a.m. Eastern Daylight Time to review first-quarter 2023 financials and provide corporate updates.

• Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023

  5/5/2023

  Jaguar Health, Inc. today announced that, effective May 2, 2023, the Company granted 100 restricted stock units (RSUs) to New Employee 1 and 4,000 RSUs to New Employee 2.

• Napo Therapeutics Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress in Abu Dhabi

  5/1/2023

  Jaguar Health, Inc. today announced that Napo Therapeutics is a Platinum Sponsor of the 9th Annual Elite Ped-GI Congress, which takes place May 4-6, 2023 in Abu Dhabi in the United Arab Emirates.

• U.S. Veterinary Oncologists Participating in a New Survey Prefer Canalevia-CA1 Over the Current Standard of Care

  4/27/2023

  Jaguar Health, Inc. announced the results of a survey of 26 U.S. veterinary oncologists regarding Canalevia-CA1, the company's U.S. Food and Drug Administration conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs.

• Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea

  4/11/2023

  Jaguar Health, Inc. today announced that patient enrollment has surpassed 90% in the Company's pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients.

• Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

  3/30/2023

  Jaguar Health, Inc. under its Jaguar Animal Health tradename for the veterinary market, announced that the Company is exhibiting at the Veterinary Cancer Society Collaborative Conference, which takes place April 19-22, 2023 in Cancun, Mexico, as part of ongoing promotional activities for Canalevia-CA1.

• Jaguar Health Reports 2022 Financial Results - Prescription Revenues up 179% to $11.9 Million

  3/27/2023

  Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided Company updates and reported consolidated financial results for the year ended December 31, 2022.

• Jaguar Health Announces Time Change for March 27th Investor Webcast to 8:00 AM EDT

  3/24/2023

  Jaguar Health, Inc. announced that the company investor webcast scheduled for Monday, March 27, 2023 to review fourth-quarter 2022 financials and provide corporate updates will now take place at 8:00 a.m. Eastern Daylight Time instead of 8:30 a.m.

• Leading Cancer Patient Advocate Kelly Shanahan, M.D., Joins Jaguar Health's Scientific Advisory Board

  3/23/2023

  Jaguar Health, Inc. and its wholly owned subsidiary Napo Pharmaceuticals announced that Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who is now a full-time independent patient advocate, has joined the Jaguar/Napo Scientific Advisory Board.

• Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates

  3/21/2023

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, March 27, 2023 at 8:30 a.m. Eastern Daylight Time to review fourth-quarter 2022 financials and provide corporate updates.

• Jaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest Communities

  3/15/2023

  Jaguar Health, Inc. announced that the Company, in advance of International Day of Forests, which takes place March 21, 2023, has achieved an important milestone related to the health of forest ecosystems, people, and communities in the Peruvian Rainforest.

• Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug

  3/13/2023

  Jaguar Health, Inc. today announced that the Company is developing an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi.

• Jaguar Health to Present at BioTrinity 2023 Conference’s R&D Spotlight on Rare Diseases

  3/2/2023

  Jaguar Health, Inc. today announced that Lisa Conte, the Company's founder, president, and CEO, is scheduled to present at the BioTrinity 2023 conference in London on Tuesday, April 25, 2023 during the R&D Spotlight session on Rare Diseases.

• FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US

  2/28/2023

  Jaguar Health today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to crofelemer for the indication of microvillus inclusion disease (MVID).

• Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer

  2/23/2023

  Jaguar Health, Inc. today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 16/617,466, titled Methods And Compositions For Treating Bile Acid Diarrhea.